The Centers for Medicare & Medicaid Services (CMS)’ TEAM (Transforming Episode Accountability Model) represents a meaningful shift from single-case metrics to episode-level accountability — a change that should be front and center in the toolkit of every healthcare value analysis leader. Where traditional value analysis often judged a technology or device on acquisition price and isolated clinical outcomes, TEAM forces organizations to evaluate how decisions affect the entire 30-day episode of care: perioperative preparation, the operative event, post-acute recovery, readmissions, and total cost across that window. For value analysis professionals, that reframing creates both risk and opportunity: risk if decisions remain narrow and siloed; opportunity if evaluation and implementation are retooled to optimize episode outcomes, reduce preventable harm, and demonstrate measurable return under episode-based payment pressures. As part of this new mandatory CMS model for targeted facilities, five specific episodes of care are monitored and measured including:
- Coronary Artery Bypass Graft (CABG)
- Major Bowel Procedure
- Lower Extremity Joint Replacement (LEJR)
- Surgical Hip and Femur Fracture Treatment (SHFFT)
- Spinal Fusion
First, embrace episode mapping as your starting point. Value analysis teams must develop explicit pathway maps for TEAM-tracked procedures that show key inflection points where product, process, or behavior influences downstream outcomes. Map clinical handoffs, implant/device interactions, environmental controls, antibiotic timing, discharge instructions, and post-discharge surveillance. Each of these nodes is a place where a product selection or a protocol change can reduce (or increase) the probability of an adverse event that will appear on the TEAM ledger. By visualizing the episode end-to-end, teams can prioritize high-yield interventions and align vendor pilots with meaningful endpoints rather than marketing claims.
Second, change what you measure. Under TEAM, traditional procurement KPIs (unit cost, immediate failure rate) are necessary but insufficient. Add episode-relevant metrics to your evaluation framework: 30-day SSI incidence, readmission related to the index procedure, ED visits within 30 days, device-related revision surgery, and total cost of care for the episode. For products that affect the intraoperative environment — such as air disinfection technologies, sterilization accessories, or implant handling tools — include process measures that capture fidelity (bundle adherence, door openings, traffic, antibiotic timing) and intermediate environmental measures (airborne bioburden, settle-plate counts) if relevant. The combination of process metrics and outcome measures lets you quantify the incremental contribution of a product in a TEAM context.
Third, design pilots and ROI with the episode in mind. Traditional single-site proof-of-concept testing should be reworked into pragmatic pilots that measure TEAM-relevant endpoints and have clear governance. A robust pilot protocol should include baseline measurement windows, matched controls or historical comparators, predefined clinical endpoints (e.g., SSI within 30 days), process adherence checks, staff training plans, safety stop rules, and a clear data-ownership agreement. Economic modeling for ROI must incorporate avoided downstream costs (reduced readmissions, fewer revision surgeries, shorter total length of episode) and sensitivity analyses — because small clinical improvements that reduce costly complications can produce outsized financial benefits under episode-based accountability.
Fourth, expand the value analysis rubric to include systems and supplier readiness. Under TEAM, suppliers are not just vendors — they are implementation partners. Evaluation checklists should require clarity on regulatory claims aligned to episode outcomes, manufacturing quality (FDA-registered facilities, ISO), supply continuity plans (backorder mitigation), user interface and IFU simplicity (human factors), and evidence of real-world impact. Insist on trial support, proctoring, and data sharing plans that permit robust post-pilot analysis. In contracts, build in outcome-focused clauses (data-sharing, milestones, publication agreements) rather than committing solely to price and volume.
Fifth, build a cross-functional governance model. TEAM performance is multidisciplinary by design. Value analysis success requires tight collaboration across infection prevention, perioperative nursing, anesthesia, supply chain, finance, quality, and clinical champions. Create a TEAM Steering Committee for each tracked procedure that meets regularly to review pilot data, address implementation barriers, and escalate resources. Use that governance forum to co-own communications, patient education, and performance dashboards so that episode gains are sustainable and scalable.
Sixth, lean into measurement infrastructure and storytelling. Establish dashboards that combine process and outcome measures and present them in an executive-friendly format tied to TEAM goals. Visuals should connect product-level changes to episode-level outcomes and financial impact. Storytelling matters: craft short narratives that demonstrate how a specific intervention prevented a readmission or shortened recovery — these humanize data for CEOs and CFOs and speed funding decisions.
Finally, prepare for the cultural work. TEAM rewards integration and continuous improvement, not single victories. Value analysis leaders should set expectations that pilots are experiments with learning built-in, and that scaling requires operational discipline. Train teams on rapid-cycle improvement methods, human factors, and data literacy so that evidence from pilots converts quickly into standardized practice.
Applying the CMS TEAM Model to healthcare value analysis means shifting from product-centric evaluation to episode-centric impact. It requires new maps, new metrics, new pilot designs, deeper supplier requirements, and stronger cross-functional governance. For organizations that do this well, the payoff is twofold: better outcomes for patients and demonstrable value for the health system in a payment environment that increasingly rewards holistic episode excellence. Value analysis professionals who retool their process now will not only protect patients — they will position their organizations to thrive under TEAM’s accountability framework.
To learn more about the CMS TEAM Model, visit: https://www.cms.gov/priorities/innovation/innovation-models/team-model.
Article by:
J. Hudson Garrett Jr., Ph.D., MSN, MPH, MBA, FNP-BC, IP-BC, PLNC, VA-BC, BC-MSLcert™, MSL-BC, CPHRM, LTC-CIP, CPPS, CAE, CPHQ, CVAHPTM, CMRP, CPXP, CDIPC, FACDONA, FAAPM, eFACHDM, FNAP, FACHE, FAPIC, FSHEA, FIDSA, FAHVAP
Dr. Garrett is the Executive Director and Executive Vice President for the Association of Healthcare Value Analysis Professionals (AHVAP) and an Adjunct Assistant Professor of Medicine in the Division of Infectious Diseases at the University of Louisville School of Medicine.
Anne Marie Orlando, MBA, BS, RN, RCIS, CVAHPTM, CMRP, PNAP, FACHDM, FAHVAP
Anne Marie is the Vice President of Clinical Services at Yankee Alliance and serves as the President of the Board of Directors for the Association of Healthcare Value Analysis Professionals (AHVAP).
Articles you may like:
Aligning Value Analysis with Strategic Priorities: Driving Quality, Outcomes, and Cost Stewardship
